Lundbeck Gets Chelsea’s Northera At A Discount, But Also Gets Challenges
This article was originally published in The Pink Sheet Daily
The Danish drugmaker will pay $530 million upfront, but analysts believe it will not have to pay out the $129 million in contingent value rights payments.
You may also be interested in...
Unmet need is high in Huntington’s disease and the protracted review of Xenazine – the only drug cleared for the disease by FDA – suggests regulatory precedent for approval based on just one efficacy endpoint and with lots of development and safety baggage.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.